WOW - excellent presentation. Looks like the smart money will be...

WOW - excellent presentation. Looks like the smart money will be accumulating at this very low price level, come back in 12 months where will the SP be after sales start rolling in late 2020 / early 2021....mmmmmmmmmmm...........$0.85 for a stab in the dark...

Global patient population of ~130k p.a at indicative US$25k per device
• No other approved products and not aware of any competition in advanced development
• Extensive Patent coverage across all key geographies out to 2024 for EU & RoW and 2028 for US Now ready to commercialise

• Approved for sale in over 28 countries via CE Mark (received April 2020) • First sales in EU & UK expected in 2H20 (COVID-19 permitting)
• Pending regulatory approvals in Australia, NZ, Hong Kong, Singapore • Breakthrough designation from FDA and pursuing US approval via Humanitarian designation in 2H20
• Manufacturing complete for commercial roll out and can be scaled rapidly for anticipated growth • Highly regarded Board & Management with extensive commercialisation experience – ex Sirtex, Cochlear & big pharma Potential for significant revenues and segmental profitability2 in CY21 and beyond
• High gross margins when at scale, with a low fixed cost base
• Concentrated and well defined hospital customer base – only modest salesforce required
• R&D time and cost sunk over past 5 years in excess of A$50mn Raising up to A$19m via Placement and Entitlement Offer at A$0.09 per share
• Funds raised will be to support sales roll out in the UK, EU and ASEAN regions
• Accelerate both commercialisation of Bile Duct Cancer in the US (post approval) and to bring forward the start of the US Pancreatic clinical trials